Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
